Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. (March 2020)

• Record Type: Journal Article
• Authors: Katzman, Martin A; Wang, Xuemei; Wajsbrot, Dalia B; Boucher, Matthieu
• Is Part Of: Journal of psychopharmacology. Volume 34:Number 3(2020)
• Page Start: 280
• Page End: 292
• Publication Date: 2020-03
• Subjects: Desvenlafaxine -- drugs for depression -- major depressive disorder -- symptom cluster -- treatment outcome -- predictive value of tests; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881119896066
• Languages: English
• ISSNs: 0269-8811

Abstract

Background: Major depressive disorder is characterized by the presence of at least five of nine specific symptoms that contribute to clinically significant functional impairment. This analysis examined the effect of desvenlafaxine (50 or 100 mg) versus placebo on symptom cluster scores and the association between early improvement in symptom clusters and symptomatic or functional remission at week 8. Methods: Using data from nine double-blind, placebo-controlled studies of desvenlafaxine for the treatment of major depressive disorder ( N =4317), the effect of desvenlafaxine 50 or 100 mg versus placebo on scores for symptom clusters based on 17-item Hamilton Rating Scale for Depression items was assessed using analysis of covariance. Association between early improvement in symptom clusters (⩾20% improvement from baseline at week 2) and symptomatic and functional remission (17-item Hamilton Rating Scale for Depression total score ⩽7; Sheehan Disability Scale score <7) at week 8 was analyzed using logistic regression. Symptom clusters based on Montgomery–Åsberg Depression Rating Scale were also examined. Results: Desvenlafaxine 50 or 100 mg was associated with significant improvement from baseline compared to placebo for all symptom clusters ( p <0.001), except a sleep cluster for desvenlafaxine 100 mg. For all symptom clusters, early improvement was significantly associated with achievement of symptomatic and functional remission at week 8 for all treatment groups ( p ⩽0.0254). Conclusion: Early improvement in symptom clusters significantly predicts symptomatic or functional remission at week 8 in patients with depression receiving desvenlafaxine (50 or 100 mg) or placebo. Importantly, patients without early improvement were less likely to remit.